Gilead should ditch remdesivir and focus on its simpler ancestor - STAT

Gilead should ditch remdesivir and focus on its simpler ancestor - STAT

Opinion: Gilead should ditch remdesivir and focus on its simpler and safer ancestor

By VICTORIA C. YAN AND FLORIAN L. MULLER

YICHUAN CAO/SIPA USA VIA AP IMAGES

Gilead Sciences is going all in on its antiviral drug remdesivir. It should also be testing its older drug, GS-441524. It works the same way, only better.

READ MORE